U.S. markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5600-0.2000 (-7.25%)
At close: 4:00PM EDT

2.5900 +0.03 (1.17%)
After hours: 6:38PM EDT

ObsEva SA

Chemin des Aulx, 12
Geneva 1228
41 22 552 38 40

Full Time Employees42

Key Executives

NameTitlePayExercisedYear Born
Mr. Brian O'CallaghanChief Exec. Officer4.29MN/A1969
Dr. Ernest LoumayeCo-Founder & Director1MN/A1952
Mr. David RenasChief Financial OfficerN/AN/A1964
Dr. Jean-Pierre Gotteland Ph.D.Chief Scientific Officer and Head of R&DN/AN/A1965
Mr. Fabien Lefebvre de LadonchampsChief Admin. OfficerN/AN/A1979
Mr. Mario Vincent CorsoSr. Director of Investor RelationsN/AN/AN/A
Ms. Delphine RenaudPersonal Assistant to the CSO and Head of R&DN/AN/AN/A
Mr. Wim SouverijnsChief Commercial OfficerN/AN/A1970
Dr. Elizabeth Ijeoma Onyemelukwe GarnerChief Medical OfficerN/AN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Corporate Governance

ObsEva SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.